脓毒症中NO通路的新视角:降低ADMA作为潜在治疗途径
该综述指出,临床前模型显示脓毒症和内皮素血症时全身NO水平升高,曾推测iNOS生成NO所致血管扩张是脓毒症低血压机制之一;但NOS抑制剂L-NAME的临床研究反而出现心脏和肺部不良事件并使脓毒症患者死亡率更高。近年发现内源性NOS抑制剂ADMA在脓毒症患者中水平升高,可导致微血管功能障碍、内皮促炎促血栓状态、炎症因子释放、氧化应激和线粒体功能障碍,多项研究显示血浆ADMA水平与脓毒症患者死亡率相关。脓毒症和缺血再灌注动物模型的临床前研究显示降低ADMA可减少器官损伤并改善生存。作者认为降低ADMA可能是减轻脓毒症进行性器官损伤和死亡率的潜在治疗途径。
要点
- 临床前脓毒症和内皮素血症模型可见全身NO水平升高,曾推测iNOS生成NO致血管扩张是脓毒症低血压机制之一。
- NOS抑制剂L-NAME的临床研究出现心脏和肺部不良事件,并使脓毒症患者死亡率更高,与预期药理作用相反。
- 脓毒症患者存在高水平ADMA,可诱导微血管功能障碍、内皮促炎促血栓状态、炎症因子释放、氧化应激和线粒体功能障碍。
- 多项研究显示血浆ADMA水平与脓毒症患者死亡率相关。
- 脓毒症和缺血再灌注动物模型的临床前研究显示,降低ADMA可减少器官损伤并改善生存;作者认为降低ADMA可能是潜在治疗途径。
适用人群与场景
- 脓毒症患者(综述讨论人群)
- 脓毒症和缺血再灌注动物模型(临床前研究)
研究设计与关键结果
- 综述汇总:临床前脓毒症和内皮素血症模型可见全身NO水平升高。
- NOS抑制剂L-NAME的临床研究出现心脏和肺部不良事件,并使脓毒症患者死亡率更高。
- 脓毒症患者存在高水平ADMA,可诱导微血管功能障碍、内皮促炎促血栓状态、炎症因子释放、氧化应激和线粒体功能障碍。
- 多项研究显示血浆ADMA水平与脓毒症患者死亡率相关。
- 脓毒症和缺血再灌注动物模型的临床前研究显示,降低ADMA可减少器官损伤并改善生存。
证据类型、等级与局限
- 证据类型:综述。
- 作者结论:L-NAME的临床发现与ADMA的临床前「床到实验室」研究提示,降低ADMA可能是减轻脓毒症进行性器官损伤和死亡率的潜在治疗途径。
- 作者指出,目前通过使用特异性降低ADMA的药物分子来检验这一途径是可行的。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为降低ADMA可能是减轻脓毒症进行性器官损伤和死亡率的潜在治疗途径。
- 原文指出,目前通过使用特异性降低ADMA的药物分子来检验这一途径是可行的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The nitric oxide pathway plays a critical role in vascular homeostasis. Increased levels of systemic nitric oxide (NO) are observed in preclinical models of sepsis and endotoxemia. This has led to the postulation that vasodilation by inducible nitric oxide synthase (iNOS) generated NO may be a mechanism of hypotension in sepsis. However, contrary to the expected pharmacological action of a nitric oxide synthase (NOS) inhibitor, clinical studies with L-NAME produced adverse cardiac and pulmonary events, and higher mortality in sepsis patients. Thus, the potential adverse effects of NO in human sepsis and shock have not been fully established. In recent years, the emerging new understanding of the NO pathway has shown that an endogenously produced inhibitor of NOS, asymmetric dimethylarginine (ADMA), a host response to infection, may play an important role in the pathophysiology of sepsis as well as organ damage during ischemia-reperfusion. ADMA induces microvascular dysfunction, proinflammatory and prothrombotic state in endothelium, release of inflammatory cytokines, oxidative stress and mitochondrial dysfunction. High levels of ADMA exist in sepsis patients, which may produce adverse effects like those observed with L-NAME. Several studies have demonstrated the association of plasma ADMA levels with mortality in sepsis patients. Preclinical studies in sepsis and ischemia-reperfusion animal models have shown that lowering of ADMA reduced organ damage and improved survival. The clinical finding with L-NAME and the preclinical research on ADMA "bed to bench" suggest that ADMA lowering could be a potential therapeutic approach to attenuate progressive organ damage and mortality in sepsis. Testing of this approach is now feasible by using the pharmacological molecules that specifically lower ADMA.
参考来源
- Singh J, Lee Y, Kellum JA, et al. A new perspective on NO pathway in sepsis and ADMA lowering as a potential therapeutic approach. Crit Care. 2022. PMID: 35962414. doi:10.1186/s13054-022-04075-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。